. "9. Findings, Conclusions, and Recommendations." New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States. Washington, DC: The National Academies Press, 1985.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
New Vaccine Development Establishing Priorities, Volume I: Diseases of Importance in the United States
Findings, Conclusions and Recommendations
This chapter presents the results obtained from the priority assessment system described in the preceding chapters. Health benefits and net costs have been calculated for each of the 22 vaccine projects,* and the candidates have been ranked accordingly. These rankings reflect assumptions made in the central analysis, presented in Chapters 1 through 7 and reiterated below. To illustrate the use of other assumptions (all considered plausible by the committee), several sets of sensitivity analyses have been performed. These examine the effects on the rankings of different perspectives on the undesirability of morbidity and death, of different discount rates, and of alternative assumptions on the probability of successful development, likely utilization, and vaccine cost.
The rankings discussed below should be used as a guide to the selection of development priorities after consideration of the assumptions and issues outlined in Chapters 3 and 8. The committee believes that one of the major strengths of this analysis is that it encourages those using it to examine all judgments and assumptions involved in the decision process. New data should be incorporated as they become available. Alternative assumptions regarding variables in the model may be incorporated as appropriate, depending on the purposes for which decision makers are using this tool.
The Central Analysis
The central analysis described below incorporates the following:
Vaccine and development characteristics described in Chapter 5, including predictions on the target population, efficacy, and vaccine cost.
The anticipated utilization rate estimated for a “no combination, no promotion” situation (Chapter 6).
The 22 projects involve 20 vaccines: the attenuated live cytomegalovirus vaccine and the varicella vaccine each have two separate target populations.
Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole. Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter.
Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.